Physician profile
Charles Perla
NPI 1730180589
$1,319.94
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,306 · 2024: $13.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $178.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $154.24 | 2019 | |
| Genzyme Corporation | $125.00 | 2019 | |
| Boston Scientific Corporation | $70.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $70.64 | 2019 | |
| Lantheus Medical Imaging, INC. | $70.45 | 2019 | |
| Amarin Pharma, INC. | $68.68 | 2019 | |
| Gilead Sciences, INC. | $67.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.55 | 2019 | |
| Biotronik INC. | $63.24 | 2019 | |
| Sanofi-Aventis U.S. LLC | $56.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.41 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.29 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $47.53 | 2019 | |
| Pfizer INC. | $45.33 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.24 | 2019 | |
| Medtronic Vascular, INC. | $23.89 | 2019 | |
| Vifor Pharma, INC. | $18.46 | 2019 | |
| Astellas Pharma US INC | $18.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.84 | 2019 | |
| Edwards Lifesciences Corporation | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Perla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.